Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander NS, Singh AK, Parker TL, Menter A, Yang X, Parsons BM, Kumar P, Kapoor P, Rosenberg AS, Zonder JA, Faber EA, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial , Lancet Oncology, 21(10): 2020,1317-1330
Richardson PG, Lee HC, Abdalla A-O, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study , Blood Cancer Journal, 10(10): 2020,106
Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma , Journal for Immunotherapy of Cancer, 8(2): 2020,e000734
AD Cohen, N Raje, J Fowler, K Mezzi, EC Sctoo, MV Dhodapkar How to train your T cells: overcoming immune dysfunction in multiple myeloma , Clinical Cancer Research, 26(7): 2020,1541-1554
Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren E, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie BG, Orlowski RZ Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma , Clin Cancer Res
, 26(15): 2020,3969-3978
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah A-O, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facun T, Hulin C, Kortum M, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Pointek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD Belantamab mafotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm randomised, open label, phase 2 study. , Lancet Oncology , 21(2): 2020,207-221
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker K, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH CRISPR-engineered T cells in patients with refractory cancer , Science, 367(6481): 2020,eaba7365
Cohen AD Myeloma: next-generation immunotherapy , Hematology. American Society of Hematology Education Program., 2019(1): 2019,266-272
Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. , Cancer Immunol Res
, 7(10): 2019,1633-1646
Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies , Blood Advances, 3(16): 2019,2487-2490
